ACTRN12609000447257
Terminated
未知
Prospective study investigating the change of ocular mucin expression on the ocular surface and in tear fluid due to contact lens wear and its correlation with contact lens clinical performance in neophytes and regular wearers with minimal lens wear in the previous one month.
Institute for Eye Research0 sites30 target enrollmentJune 12, 2009
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Institute for Eye Research
- Enrollment
- 30
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;
- •Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator;
- •Have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses;
- •Has vision correctable to at least 6/12 (20/40\) or better in each eye with contact lenses.
Exclusion Criteria
- •Regular contact lens wearers;
- •Pre\-existing ocular irritation that would preclude contact lens fitting;
- •Any ocular condition that may preclude safe wearing of contact lenses e.g. active corneal infection, severe dry eye, reduced corneal sensitivity, exophthalmos/lagophthalmos, facial nerve palsy;
- •Active corneal infection (bacterial, viral, fungal or protozoan) or any active ocular disease such as iritis, corneal edema or corneal dystrophies, including anterior membrane dystrophy that would affect wearing of contact lenses;
- •Use of any of the following medications (including steroids) up to 12 weeks prior to start of the clinical trial, or during the course of the trial:
- •Ocular medication, category S3 and above;
- •Any systemic or topical medications that will affect ocular physiology or the performance of the lenses e.g. anti\-acne medications such as Roaccutane and corticosteroid or immunosuppressant medications such as Hydrocortisone, Prednisolone;
- •Any systemic disease that may affect ocular health e.g. diabetes, Graves disease, and auto\-immune diseases such as ankolysing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosis;
- •Conditions such as systemic hypertension do not automatically exclude prospective participants;
- •Eye surgery within 12 weeks immediately prior to enrolment for this trial;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A study to measure pressure changes in eye while a person undergoes surgery for spine fracture lying on his back during surgeryHealth Condition 1: W19- Unspecified fallCTRI/2019/01/017211Department of Anaesthesiology
Not yet recruiting
Not Applicable
Visual disturbances of patients following operatioHealth Condition 1: O- Medical and SurgicalCTRI/2023/03/050562GCS medical college and hospital
Recruiting
Not Applicable
Observation of changes in ocular findings before and after the use of the IL-4 and 13 antibody preparation dupilumabJPRN-UMIN000038675Keio University150
Not yet recruiting
Phase 2
A study to see changes after antiVEFG injection ranibizumab in Retinal Vein Occlusion using OCT Angiography patients at SMS hospitalCTRI/2023/08/056558SMS Medical College and Hospital Jaipur
Active, not recruiting
Phase 1
A clinical trial on the changes in ocular signs and symptoms in patientswith ocular hypertension or open-angle glaucoma switched from Ganfort® eye drops to Taptiqom® eye drops.Glaucoma or Ocular HypertensionMedDRA version: 18.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 18.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 18.0Level: PTClassification code 10074026Term: Exfoliation glaucomaSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2014-005273-37-DESanten Oy120